tiprankstipranks
Trending News
More News >
Carl Zeiss Meditec (DE:AFX)
XETRA:AFX
Advertisement

Carl Zeiss Meditec (AFX) AI Stock Analysis

Compare
111 Followers

Top Page

DE:AFX

Carl Zeiss Meditec

(XETRA:AFX)

Select Model
Select Model
Select Model
Neutral 67 (OpenAI - 4o)
Rating:67Neutral
Price Target:
€48.00
▲(1.35% Upside)
Carl Zeiss Meditec's overall stock score is driven by strong financial performance and moderate technical indicators. The company's profitability and low debt enhance its financial stability, but growth moderation and liability risks are concerns. The technical analysis indicates short-term bullishness, but longer-term trends are less favorable. Valuation metrics suggest the stock is fairly valued, with a moderate dividend yield.
Positive Factors
Strong Profitability
The company's robust profitability and operational efficiency indicate a well-managed business with effective cost control, supporting long-term financial health.
Low Debt Levels
Low debt levels enhance financial stability, reducing risk and providing flexibility for future investments and growth opportunities.
Innovative Product Portfolio
A focus on innovation in medical technology ensures competitive advantage and sustained demand for its products, supporting long-term growth.
Negative Factors
Moderating Revenue Growth
Slowing revenue growth could indicate market saturation or increased competition, potentially impacting future expansion and profitability.
Substantial Liabilities
High liabilities can limit financial flexibility and increase risk, necessitating careful management to maintain stability and growth potential.
Fluctuating Free Cash Flow
Variability in free cash flow can affect the company's ability to reinvest in growth initiatives and manage financial obligations, impacting long-term strategy.

Carl Zeiss Meditec (AFX) vs. iShares MSCI Germany ETF (EWG)

Carl Zeiss Meditec Business Overview & Revenue Model

Company DescriptionCarl Zeiss Meditec AG is a leading global medical technology company that specializes in developing and manufacturing innovative solutions in the fields of ophthalmology and microsurgery. The company operates primarily in two segments: Ophthalmology and Microsurgery. Its core products include surgical microscopes, intraocular lenses, diagnostic devices, and software solutions that enhance the precision and effectiveness of medical procedures.
How the Company Makes MoneyCarl Zeiss Meditec generates revenue through multiple streams, primarily by selling medical devices and systems to hospitals, clinics, and healthcare professionals. The company earns significant income from the sale of surgical equipment and diagnostic devices, particularly in the ophthalmology sector, where it provides advanced technologies for cataract and refractive surgeries. Additionally, recurring revenue is generated through the sale of consumables, maintenance services, and software updates. Strategic partnerships with healthcare providers and technology firms enhance its market reach and product offerings, further contributing to its revenue generation. The company's strong focus on research and development allows it to innovate continuously, maintaining a competitive edge in the medical technology market.

Carl Zeiss Meditec Financial Statement Overview

Summary
Carl Zeiss Meditec demonstrates strong profitability and operational efficiency with a solid Gross Profit Margin and consistent Net Income growth. The company maintains a low debt profile, enhancing financial stability, but growth rates have moderated, and liabilities pose a potential risk.
Income Statement
Carl Zeiss Meditec shows a strong Gross Profit Margin and consistent Net Income growth, indicating solid profitability and operational efficiency. The Revenue Growth Rate is positive but has slowed down in recent years, suggesting a potential plateau in growth. Both EBIT and EBITDA margins are healthy, indicating good control over costs.
Balance Sheet
The company's Debt-to-Equity Ratio is low, showing strong solvency and low reliance on debt financing. ROE is robust, emphasizing effective use of equity to generate profits. However, the Equity Ratio is relatively low due to substantial liabilities, which could pose a risk if not managed carefully.
Cash Flow
The company has a stable Free Cash Flow, although growth has been modest. Operating Cash Flow to Net Income Ratio is strong, reflecting efficient cash generation from operations. However, Free Cash Flow to Net Income has fluctuated, indicating variability in cash availability for reinvestment and financing.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue2.18B2.07B2.09B1.90B1.65B1.34B
Gross Profit1.13B1.09B1.21B1.13B967.21M745.52M
EBITDA389.80M403.06M502.77M482.36M409.21M266.41M
Net Income150.13M178.73M290.40M293.91M236.28M122.39M
Balance Sheet
Total Assets0.003.39B3.03B2.82B2.40B2.01B
Cash, Cash Equivalents and Short-Term Investments26.55M20.29M10.60M7.73M7.44M5.20M
Total Debt0.00151.35M155.70M127.90M121.27M68.61M
Total Liabilities-2.09B1.34B860.02M792.73M718.59M562.73M
Stockholders Equity2.09B2.04B2.16B2.02B1.66B1.43B
Cash Flow
Free Cash Flow109.01M95.11M137.00M106.23M296.56M133.54M
Operating Cash Flow169.31M247.32M250.86M188.20M362.66M178.53M
Investing Cash Flow-460.40M-412.31M-110.98M-148.89M-75.20M-71.95M
Financing Cash Flow309.56M176.25M-135.09M-38.24M-285.89M-122.96M

Carl Zeiss Meditec Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price47.36
Price Trends
50DMA
43.90
Positive
100DMA
48.51
Negative
200DMA
53.09
Negative
Market Momentum
MACD
0.82
Negative
RSI
59.08
Neutral
STOCH
87.82
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:AFX, the sentiment is Neutral. The current price of 47.36 is above the 20-day moving average (MA) of 44.78, above the 50-day MA of 43.90, and below the 200-day MA of 53.09, indicating a neutral trend. The MACD of 0.82 indicates Negative momentum. The RSI at 59.08 is Neutral, neither overbought nor oversold. The STOCH value of 87.82 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for DE:AFX.

Carl Zeiss Meditec Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
70
Outperform
€13.54B20.744.83%3.05%0.53%23.79%
69
Neutral
€14.28B98.105.01%0.38%5.82%59.90%
67
Neutral
€4.08B25.787.48%1.27%5.21%-39.36%
66
Neutral
€1.06B28.8717.61%0.96%9.42%9.54%
64
Neutral
€1.27B14.496.87%2.64%-0.03%-14.15%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
51
Neutral
€1.31B64.150.10%-18.82%-113.85%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
DE:AFX
Carl Zeiss Meditec
47.36
-14.62
-23.59%
DE:BIO
Biotest
38.00
-3.60
-8.65%
DE:DRW3
Draegerwerk AG & Co. KGaA
77.00
31.64
69.74%
DE:EUZ
Eckert & Ziegler Strahlen und Medizintechnik
17.45
2.93
20.17%
DE:FME
Fresenius Medical Care AG & Co. KGaA
47.17
9.21
24.27%
DE:SRT
Sartorius
193.60
-6.55
-3.27%

Carl Zeiss Meditec Corporate Events

Carl Zeiss Meditec’s New Study on Cataract Surgery Outcomes: What Investors Need to Know
Jul 24, 2025

Study Overview: Carl Zeiss Meditec is conducting a clinical study titled ‘EPIC: Evaluation of the Postoperative Cataract Surgery Outcomes in Patients With Prior Corneal Laser Vision Correction Implanted With the CT LUCIA Intraocular Lens.’ The study aims to assess the visual and refractive outcomes in patients who have undergone myopic corneal laser vision correction and are now receiving the CT LUCIA 621P intraocular lens during cataract surgery. This research is significant as it seeks to improve understanding of postoperative results in this specific patient group.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 14, 2025